Hossein Rahnama, CEO of Flybits, on CBC’s Lang & O’Leary Exchange
![Hossein Rahnama on Lang & O'Leary Hossein Rahnama on Lang & O'Leary](https://tiap.ca/wp-content/uploads/2012/08/Rahnama-on-Lang-OLeary-300x169.png)
Hossein Rahnama, CEO of Flybits, a MaRS Innovation spin-off company, appeared on CBC’s Lang and O’Leary Exchange on August 24, 2012.
Watch Rahnama’s interview on CBC’s Media Player. The interview begins at the 13:40 mark and runs to 19:30.
Rahnama, who is also a professor at Ryerson University and and research director at Ryerson’s Digital Media Zone, was recently named to the MIT Technology Review’s prestigious 35 Inventors Under 35 list for 2012 along with fellow MaRS Innovation inventor Joyce Poon.
He describes his context-aware mobile technology, the importance of adapting research to solve real-world problems, the advantages to running a start-up in Toronto, and growing Flybits while keeping the business in Canada.
Two MI inventors named to MIT’s 35 inventors under 35 list
![Joyce Poon Joyce Poon](https://tiap.ca/wp-content/uploads/2012/08/Joyce-Poon-300x200.png)
Professors Joyce Poon and Hossein Rahnama, who each have inventions within MaRS Innovation’s portfolio of spin-off companies and licenseable technologies, have been named to the MIT Technology Review‘s prestigious 35 Inventors Under 35 list for 2012.
Poon, an assistant professor of electrical and computer engineering at the University of Toronto, was recognized for, according to MIT’s Technology Review, “creating new optical modulators with microscopic loop-the-loops through which light can shuttle data between servers and even from chip to chip within a single server.” She is working with MaRS Innovation to license her technology.
OtoSim CEO Andrew Sinclair: When entering the market, expect the unexpected
Andrew Sinclair, CEO of OtoSim Inc. and a senior director at MaRS Innovation, describes some of the unexpected twists and turns OtoSim has weathered in bringing their product to market in…
BioCentury Features Xagenic’s PCR-Based Infection-Diagnosis Technology
Xagenic, a MaRS Innovation spin-off company, was featured in the most recent issue of BioCentury. Here's an excerpt (the article only available to BioCentury subscribers): PCR-based diagnosis of infections can…
Los Angeles Times covers Dr. Gregory Czarnota’s cancer therapy technology
The Los Angeles Times featured Dr. Gregory Czarnota’s research in their Science Now section on July 10, 2012, which reports on discoveries from the world of science and medicine (update: the article is no longer available online).
Czarnota, a researcher at the Sunnybrook Health Sciences Centre, is working with MaRS Innovation to license his patented technology: radiosensitization of tumour cells using a combination of microbubbles and targeted, high-intensity, focused ultrasound.
MaRS Innovation’s Lead Start-Up Completes $20 Million Series B
Xagenic’s financing round to test platform and first diagnostic assay, continue product development and begin FDA submission Toronto, ON (December 2, 2013) — MaRS Innovation’s first start-up company, Xagenic Inc.,…
Business Without Borders features Encycle Therapeutics, Raphael Hofstein
Encycle Therapeutics, a MaRS Innovation spin-off company, was featured by Business Without Borders' High Tech section in a Q&A profile with MI's President and CEO, Raphael Hofstein. Here's an excerpt:…
Flybits featured as Canadian tech export in UKTI Youtube video
U.K. Trade and Investment (UKTI) has posted a Youtube video featuring Canadian companies looking to expand their operations to Britain.
Flybits, a Mars Innovation spin-off company, was among three companies to be profiled:
http://www.youtube.com/watch?v=9VrtJuSkYqY
Flybits is launching a corporate presence in East London’s Tech City, which is also known as the Silicon Roundabout.
Raphael Hofstein’s guest blog for the Ontario Ministry of Economic Development and Innovation
At the 2012 BIO International Convention in Boston this week, MaRS Innovation, The Québec Consortium for Drug Discovery (CQDM), the Ontario Brain Institute and the Ontario Centres of Excellence announced we are launching a new life sciences funding program within the Ontario-Québec Corridor.
The Ontario-Québec Life Sciences Corridor was itself announced at the 2011 BIO International Convention. Shortly thereafter, Max Felhmann, president and CEO of CQDM, and Raphael Hofstein, president and CEO of MaRS Innovation, decided to collaborate on a joint pilot project, which has produced Encycle Therapeutics.